Anticoagulant plus antiplatelet therapy for atrial fibrillation : Cost-utility of combination therapy with non-vitamin K oral anticoagulants vs. warfarin.
Kerstin BodeG HindricksJ M Ten BergP WhittakerPublished in: Herz (2018)
The derived ICER was 13,168.50 € per QALY, consistent with NOACs being cost-effective vs. warfarin when anticoagulation is used with antiplatelet agents. Nevertheless, country-, practice-, and patient-related factors influence the ICER. Our cost-utility calculation should be used a starting point for decision-making.
Keyphrases
- oral anticoagulants
- atrial fibrillation
- antiplatelet therapy
- combination therapy
- percutaneous coronary intervention
- decision making
- acute coronary syndrome
- left atrial
- catheter ablation
- direct oral anticoagulants
- left atrial appendage
- heart failure
- primary care
- case report
- healthcare
- venous thromboembolism
- coronary artery disease
- quality improvement